Skip to content

MyMD Pharmaceuticals Enrolls First Patient in Stage 2 Scientific Trial of MYMD-1 as a Therapy for Delaying Aging and also Expanding Healthy Life Expectancy

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc – Stock Price, Quote and News (” MyMD” or “the Business”), a clinical phase pharmaceutical firm devoted to prolonging healthy life expectancy, today introduced that the very first person has been enrolled in the Business’s Stage 2 medical test of lead candidate MYMD-1, an oral immune regulatory authority medication, as a treatment for postponing aging and expanding healthy and balanced life expectancy.

The primary endpoint for the Phase 2 double-blind, placebo-controlled professional trial is to accomplish a reduction in the flowing levels of (TNF-α), growth death element receptor I (TNFRI) as well as IL-6. TNF-α as well as IL-6 are the proteins in the body that create swelling and also aid activate the process of aging. The additional actions of the trial will certainly be the safety and security, tolerability, as well as pharmacokinetics in this populace of individuals.

” In a Stage 1 clinical trial of MYMD-1, we showed the medication’s statistically significant efficiency in minimizing levels of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has approved TNF-α decrease as the main endpoint for our Phase 2 research, which our team believe placements us well for a successful Phase 2 end result,” said Chris Chapman, M.D., President, Supervisor as well as Chief Medical Police Officer of MyMD. “The initiation of individual registration in this research advances our goal to reduce the aging procedure, stop loss of muscle cells in aging, limit frailty, as well as prolong healthy and balanced lifespan.”

MyMD has stated that there are no FDA-approved drugs for treating aging conditions and also extending healthy and balanced life expectancy human beings, a market anticipated to be a minimum of $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most recommended medications by income, an international market of roughly $40 billion each year,2 and, according to Nature Aging journal,3 a slowdown in maturing that would enhance life span by one year is worth $38 trillion as well as by ten years deserves $367 trillion.

In addition to aging, MYMD-1’s distinctive action in regulating the body immune system as well as dealing with chronic swelling is being established for the treatment of autoimmune condition, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetic issues, as well as inflammatory digestive tract illness.

” We intend to begin creating methods for a Phase 2 pilot study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The increasing occurrence of rheumatoid joint inflammation as well as other autoimmune as well as inflammatory illness are driving need for TNF inhibitors like MYMD-1, as well as we believe our by mouth carried out medication with very reduced toxicity would be turbulent to the $60 billion market for RA if accepted by the FDA for this indication.”

Rheumatoid joint inflammation affects around 40 million individuals globally.4.

Concerning MYMD-1.

Initially developed for autoimmune conditions, MYMD-1’s primary purpose is to reduce the aging process, protect against sarcopenia and also frailty, and prolong healthy lifespan. Due to the fact that it can cross the blood-brain obstacle as well as gain access to the central nerves (CNS), MYMD-1 is additionally positioned to be a possible therapy for brain-related conditions. Its system of activity and efficiency in illness including multiple sclerosis (MS) and thyroiditis have actually been studied with partnerships with a number of academic institutions. MYMD-1 is additionally showing pledge in pre-clinical research studies as a possible therapy for blog post- COVID-19 issues and as an anti-fibrotic and also anti-proliferation restorative.

MYMD-1 has actually shown efficiency in pre-clinical studies in controling the body immune system by carrying out as a selective inhibitor of growth death factor-alpha (TNF-α), a motorist of chronic inflammation. Unlike other therapies, MYMD-1 has been shown in these pre-clinical researches to precisely block TNF-α when it ends up being overactivated in autoimmune conditions and also cytokine tornados, yet not block it from doing its regular job of being a very first -responder to any kind of regular type of moderate infection. MYMD-1’s convenience of dental dosing is an additional differentiator compared to presently readily available TNF-α blockers, every one of which call for shipment by shot or mixture. No authorized TNF inhibitor has ever before been dosed by mouth. Additionally, the medication is not immunosuppressive and also has not been shown to cause the significant adverse effects usual with standard therapies that deal with swelling.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional phase pharmaceutical company devoted to prolonging healthy and balanced lifespan, is focused on creating two novel restorative platforms that deal with the reasons for condition instead of only resolving the symptoms. MYMD-1 is a drug system based upon a clinical phase tiny particle that manages the immune system to manage TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to postpone aging, rise longevity, as well as deal with autoimmune diseases and COVID-19- associated depression. The Company’s second medication platform, Supera-CBD, is being developed to treat chronic pain, dependency as well as epilepsy. Supera-CBD is a novel artificial by-product of cannabidiol (CBD) and is being developed to deal with and also improve upon the swiftly expanding CBD market, that includes both FDA authorized drugs and CBD items not currently managed as drugs. For additional information, see www.mymd.com.